Vestal Point Capital’s Fulcrum Therapeutics FULC Stock Holding History

Vestal Point Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,100,000	Closed	-$8.44M	–	79
2026 Q1	$8.44M	Buy	1,100,000 +150,000	+16%	+$1.39M	0.24%	68
2025 Q4	$10.7M	Buy	+950,000	New	+$9.67M	0.37%	48
2024 Q3	–	Sell	-1,160,000	Closed	-$7.19M	–	77
2024 Q2	$7.19M	Buy	1,160,000 +465,000	+67%	+$3.52M	0.54%	40
2024 Q1	$6.56M	Sell	695,000 -330,000	-32%	-$2.95M	0.54%	37
2023 Q4	$6.92M	Buy	+1,025,000	New	+$4.55M	0.73%	30

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital's FULC Position: Q2 2026 in Review

Vestal Point Capital sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 1,100,000 shares — an estimated $8.44M sold.

Vestal Point Capital first reported a position in FULC in Q4 2023 and held it in 5 quarters. The position peaked at $10.7M in Q4 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Vestal Point Capital reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 1,100,000 Fulcrum Therapeutics shares in Q2 2026, an estimated $8.44M.
Vestal Point Capital first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 5 quarters.
Vestal Point Capital's Fulcrum Therapeutics position peaked at $10.7M in Q4 2025.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.